Matthew Osman, Legit
This one-day event will bring together industry leaders, thought leaders, innovators and disruptors around the topic of Sustainability. We will explore sustainability and its business implications across industries from the perspective of senior corporate leaders, startup founders, investors and world class MIT faculty via keynotes, panel discussion, lightning talks and startup exhibits. Topic should appeal to a broad cross section of senior executives regardless of industry.
How should corporates set and reach their sustainability goals? What work are industry leaders doing today to decarbonize their operations, and what themes are emerging? How should we think about sustainability partnerships with competitors, government, investors and startups? Where are investors putting their capital? What problems can startups solve for corporates, and what do effective startup-corporate partnerships look like? These are just some of the questions we will address.
Join us to be part of the conversation, and to be part of the solution.
The event is jointly organized by the MIT Startup Exchange and the Industrial Liaison Program (ILP). MIT Startup Exchange actively promotes collaboration and partnerships between MIT-connected startups and industry, exclusively members of MIT's Industrial Liaison Program. “MIT-connected” startups are based on licensed MIT technology, or are founded by MIT faculty, staff, or alumni. Currently, over 1,000 startups are registered with MIT Startup Exchange.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.